TrialBlood cancer journal2016

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.

J J Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.